drugset
drugset / Trial / NCT01936480

Genetics of QT Response to Moxifloxacin

NCT01936480 ↗

Phase 4 Terminated 51 enrolled Massachusetts General Hospital
RandomizedCrossoverTriple-blindPrevention

Summary

The purpose of this study is to assess the ability of common genetic variants in aggregate to predict drug-induced QT prolongation in healthy subjects using moxifloxacin.

Timeline

Start
2013-10
Primary completion
2019-06-19
Completion
2019-06-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Moxifloxacin Small molecule 400 mg —

Indications

cardiac rhythm disease